Parabilis Medicines, Inc. Common Stock (PBLS) - Total Liabilities
Based on the latest financial reports, Parabilis Medicines, Inc. Common Stock (PBLS) has total liabilities worth $127.53 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Parabilis Medicines, Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Parabilis Medicines, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Parabilis Medicines, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Parabilis Medicines, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Parabilis Medicines, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bravida Holding AB
ST:BRAV
|
Sweden | Skr14.22 Billion |
|
Beiqi Foton Motor Co Ltd
SHG:600166
|
China | CN¥46.16 Billion |
|
Grupo Cementos de Chihuahua S.A.B. de C.V
MX:GCC
|
Mexico | MX$1.29 Billion |
|
Sparebank 1 SMN
OL:MING
|
Norway | Nkr225.19 Billion |
|
WisdomTree Inc.
NYSE:WT
|
USA | $1.23 Billion |
|
Bains Mer Monaco
PA:BAIN
|
France | €596.51 Million |
|
Seek Ltd
AU:SEK
|
Australia | AU$1.88 Billion |
|
Hyundai Construction Equipment Co Ltd
KO:267270
|
Korea | ₩4.47 Trillion |
Liability Composition Analysis (2024–2025)
This chart breaks down Parabilis Medicines, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Parabilis Medicines, Inc. Common Stock's balance sheet.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Parabilis Medicines, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Parabilis Medicines, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $97.34 Million | +4.88% |
| 2024-12-31 | $92.81 Million | -- |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more